Bristol's Pipeline Finally Has a Pulse — the Market Is Still Watching Eliquis

A quarter of first-in-class readouts and a raised guide, shadowed by a $1.5B–$2B 2027 cliff.

BMY · Earnings Call · 2026-10-29

The beat is not the story

Bristol's Q3 was another respectable grind: total revenue of $13.0B, up 6% year over year and 13% sequentially, with the growth portfolio up 12% to $7.7B and eight products now annualizing above $1B. The CEO framed it as continuity, not revelation: “We reported another quarter of double digit growth in our growth portfolio and progressed our plans to derisk the pipeline to position the company for long term success.” — Christopher S. Boerner, Board Chair and Chief Executive Officer · 2026-10-29 That is the right frame, but it is not why this call matters. The reported EPS guide raise was partly optical: the quarter carried a $0.58 per-share acquired IPR&D and licensing charge, so the underlying guidance lift was closer to $0.15. The real change is the pipeline scorecard. In roughly two months Bristol logged positive registrational data for Symvexis PFS, admilparant in IPF, RAISE 101 in GEP-NETs, and Arlocell in post-BCMA myeloma. That is no longer a promise; it is a launch stack forming.

Excluding the third quarter acquired in process R&D charges and licensing income of $0.58 per share, the midpoint of our 2026 non GAAP EPS guidance would have increased by approximately $0.15 per share. After including the $0.58 per share previously referenced, our expected non GAAP EPS guidance range for 2026 is now $6.35 to $6.55.
David V. Elkins, Chief Financial Officer · 2026-10-29

From shots on goal to launch stack — but not all clean

The most important company-specific signal is the migration of Bristol's keyword map toward oncology and hematology execution. Symvexis is now the commercial name in the CELMoD story, and management is already selling the launch: “we are excited to have launched Symvexis. it is the first approved CELMoD in the market.” — Adam Lenkowsky, Chief Commercialization Officer · 2026-10-29 The old Iberdomide label is fading from the top-keyword list as the brand name takes over — a small but telling shift from pipeline language to commercial language. Behind it sits a broader CELMoD platform, plus a radiopharmaceutical platform that just produced the first Phase 3 win for an alpha emitter after lutetium. The GEP-NET opportunity is modest in revenue terms, but it validates a modality Bristol can reuse across liver, prostate and other targeted radiotherapy programs. Admilparant is the bigger commercial swing, and it is also the messiest. The 60mg dose hit the primary endpoint in IPF with a favorable safety profile; the 120mg dose did not reach statistical significance on FVC decline. That is exactly the kind of detail a bull and bear can both cite. “1 120 milligram going to your question, we have seen an improvement, a decline in FVC but not statistically significant.” — Cristian Massacesi, Chief Medical Officer, Head of Drug Development · 2026-10-29 Management leaned hard on tolerability, where existing IPF therapies still suffer from GI and cough burdens, and on the idea that the market can double as switch and add-on use expands. “Even with the advent of newer therapies, GI tolerability and cough, they are challenging to manage, especially in an older comorbid patient population.” — Adam Lenkowsky, Chief Commercialization Officer · 2026-10-29 That is a credible commercial argument, but the 120mg miss gives skeptics a clean talking point.

Eliquis is still the antagonist

Nothing in the quarter changes the central financial fact: Eliquis is still doing the heavy lifting and is still heading toward a cliff. Q3 Eliquis revenue was $4.7B, up 26%, driven by net price, demand and share gains. But Q4 includes the European loss of exclusivity, and 2027 carries a $1.5B–$2B step-down. The CFO was direct: “we anticipate that $1.5 billion to $2 billion step down in 2027.” — David V. Elkins, Chief Financial Officer · 2026-10-29 This is not new. On the prior call, the same number was already the anchor: “we still expect the $1.5 billion to $2 billion step down in 2027 that we referenced on the Q1 call.” — Adam Lenkowsky, Chief Commercial Officer · 2026-07-30 The market knows the cliff is coming. What it does not yet know is whether the replacement portfolio can grow fast enough to make the trough shallow and short. The balance sheet helps but is not unlimited: effective net cash was -$32.4B, while interest coverage was 10.0x. Gross margin was 71.3%, down 1.2pp year over year. Bristol can fund the dividend and the pipeline, but it cannot casually buy its way out of the Eliquis hole.

What the tape and cross-section say

The stock has started to vote, but not decisively. BMY is up 11.6% over the last 90 trading days, yet it sits 9.8% below its September peak and still 24.3% below the 2022 high. That is a market that has begun to pay for pipeline news but has not re-rated the full replacement story. The global cross-section also warns against over-reading Bristol's oncology keywords as unique: small cell lung cancer and PD-(L)1/VEGF combinations are sector-wide debates, and Bristol's Pumitamig commentary sits inside a crowded field rather than defining it. The company-specific edge remains in CELMoDs, radiopharma and the IPF/PPF franchise. Meanwhile, business development remains a top capital-allocation priority, as it has for several quarters: “Business development, as you know and as we've discussed repeatedly, continues to be a top allocation priority.” — Christopher Boerner, Board Chair and Chief Executive Officer · 2026-07-30 The difference now is that Bristol has more internal pipeline wins to protect, which raises the bar for any deal. The call's real tension is therefore simple: Bristol is no longer asking the market to believe in its pipeline on faith. It is asking the market to pay for it before Eliquis stops paying. Q3 showed the first part is finally happening. The second part is still unresolved.